A Calibration Approach to Transportability with Observational Data
暂无分享,去创建一个
[1] T. Brennan,et al. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. , 2012, The American journal of medicine.
[2] Vilmundur Gudnason,et al. Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death , 2011 .
[3] Elias Bareinboim,et al. Causal inference and the data-fusion problem , 2016, Proceedings of the National Academy of Sciences.
[4] Lawrence A Leiter,et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.
[5] S. Lai,et al. Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease , 2013, Diabetes Care.
[6] Robert A Greevy,et al. Comparative Effectiveness of Sulfonylurea and Metformin Monotherapy on Cardiovascular Events in Type 2 Diabetes Mellitus , 2012, Annals of Internal Medicine.
[7] Xiaofei Wang,et al. Integrative analysis of randomized clinical trials with real world evidence studies , 2020 .
[8] D. Wysowski,et al. Use of Antidiabetic Drugs in the U.S., 2003–2012 , 2014, Diabetes Care.
[9] K. C. G. Chan,et al. Globally efficient non‐parametric inference of average treatment effects by empirical balancing calibration weighting , 2016, Journal of the Royal Statistical Society. Series B, Statistical methodology.
[10] Michael G Hudgens,et al. Generalizing Study Results: A Potential Outcomes Perspective. , 2017, Epidemiology.
[11] Andrzej Stachurski,et al. Parallel Optimization: Theory, Algorithms and Applications , 2000, Parallel Distributed Comput. Pract..
[12] L. Geiss,et al. Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data , 2018, The Lancet.
[13] Sherri Rose,et al. Targeted Maximum Likelihood Estimation for Causal Inference in Observational Studies , 2017, American journal of epidemiology.
[14] Elizabeth Selvin,et al. Trends in Prevalence and Control of Diabetes in the United States, 1988–1994 and 1999–2010Trends in Prevalence and Control of Diabetes in the United States , 2014 .
[15] Mark J van der Laan,et al. Robust estimation of encouragement design intervention effects transported across sites , 2017, Journal of the Royal Statistical Society. Series B, Statistical methodology.
[16] Daniel O. Scharfstein,et al. Causal Inference for Comprehensive Cohort Studies. , 2019, 1910.03531.
[17] Elias Bareinboim,et al. External Validity: From Do-Calculus to Transportability Across Populations , 2014, Probabilistic and Causal Inference.
[18] M. Fischereder,et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.
[19] L. Geiss,et al. Prevalence and incidence trends for diagnosed diabetes among adults aged 20 to 79 years, United States, 1980-2012. , 2014, JAMA.
[20] T. Brennan,et al. Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study. , 2014, JAMA internal medicine.
[21] S. Cole,et al. Generalizing evidence from randomized clinical trials to target populations: The ACTG 320 trial. , 2010, American journal of epidemiology.
[22] S. Geman,et al. Nonparametric Maximum Likelihood Estimation by the Method of Sieves , 1982 .
[23] A. Vaag,et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. , 2011, European heart journal.
[24] D. Rubin. For objective causal inference, design trumps analysis , 2008, 0811.1640.
[25] S. Majumdar,et al. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. , 2002, Diabetes care.
[26] R. Guthrie. Canagliflozin and cardiovascular and renal events in type 2 diabetes , 2018, Postgraduate medicine.
[27] F. Porzsolt,et al. Using machine learning to predict laboratory test results , 2016, Annals of clinical biochemistry.
[28] John B Buse,et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.
[29] Stephen R Cole,et al. Transportability of Trial Results Using Inverse Odds of Sampling Weights. , 2017, American journal of epidemiology.
[30] Neha J. Pagidipati,et al. Effects of Once‐Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes , 2017, The New England journal of medicine.
[31] Joseph Kang,et al. Demystifying Double Robustness: A Comparison of Alternative Strategies for Estimating a Population Mean from Incomplete Data , 2007, 0804.2958.
[32] S. Saydah,et al. Trends and Disparities in Cardiovascular Mortality Among U.S. Adults With and Without Self-Reported Diabetes, 1988–2015 , 2018, Diabetes Care.
[33] Desmond E. Williams,et al. Changes in diabetes-related complications in the United States, 1990-2010. , 2014, The New England journal of medicine.
[34] L. Stefanski,et al. The Calculus of M-Estimation , 2002 .
[35] D. Rubin. Estimating causal effects of treatments in randomized and nonrandomized studies. , 1974 .
[36] Kevin P. Josey,et al. A framework for covariate balance using Bregman distances , 2019, Scandinavian Journal of Statistics.
[37] J. Robins,et al. Estimation of Regression Coefficients When Some Regressors are not Always Observed , 1994 .
[38] Maria Mori Brooks,et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. , 2009, The New England journal of medicine.
[39] Jianqing Fan,et al. Improving Covariate Balancing Propensity Score : A Doubly Robust and Efficient Approach ∗ , 2016 .
[40] Desmond E. Williams,et al. Changes in diabetes-related complications in the United States. , 2014, The New England journal of medicine.
[41] E. Boyko,et al. Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy , 2013, Diabetologia.
[42] J. Lunceford,et al. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study , 2004, Statistics in medicine.
[43] D. Horvitz,et al. A Generalization of Sampling Without Replacement from a Finite Universe , 1952 .
[44] J. Gross,et al. The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials , 2016, PLoS medicine.
[45] J. Saaddine,et al. Achievement of goals in U.S. diabetes care, 1999-2010. , 2013, The New England journal of medicine.
[47] M. J. van der Laan,et al. The International Journal of Biostatistics Targeted Maximum Likelihood Learning , 2011 .
[48] C. Särndal,et al. Calibration Estimators in Survey Sampling , 1992 .
[49] P. Wilson,et al. Diabetes Mellitus–Related All‐Cause and Cardiovascular Mortality in a National Cohort of Adults , 2019, Journal of the American Heart Association.
[50] D. Rubin,et al. The central role of the propensity score in observational studies for causal effects , 1983 .
[51] D. Wysowski,et al. Use of Antidiabetic Drugs in the , 2014 .
[52] S. Suissa,et al. Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies , 2017, Diabetes Care.
[53] A. Tsiatis. Semiparametric Theory and Missing Data , 2006 .
[54] Eric Q. Wu,et al. Comparative Effectiveness Without Head-to-Head Trials , 2012, PharmacoEconomics.